Study Title

[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin

Study Details

Description:

The investigators will determine the proportion of CUP patients in whom the primary tumor can be identified by [18F]F-FAPI PET-CT.

Sponsor:

Erasmus Medical Center

Contacts:

Sophie Veldhuijzen van Zanten, MD, PhD

fapiforcup@erasmusmc.nl

0107042006

Government Study Link:

NCT06644716 - Click here to see study on

ClinicalTrials.gov

Drug Details

[18F]F-FAPI
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • FAP

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468